Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Cencora, Inc. $COR Stock Position Raised by Valley National Advisers Inc.

Cencora logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

Valley National Advisers Inc. raised its position in Cencora, Inc. (NYSE:COR - Free Report) by 3,859.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 7,246 shares of the company's stock after buying an additional 7,063 shares during the quarter. Valley National Advisers Inc.'s holdings in Cencora were worth $2,176,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Cencora during the second quarter worth about $5,154,136,000. Bank of America Corp DE boosted its position in Cencora by 6.9% during the first quarter. Bank of America Corp DE now owns 4,138,388 shares of the company's stock worth $1,300,033,000 after purchasing an additional 267,318 shares in the last quarter. Amundi boosted its position in Cencora by 43.5% during the second quarter. Amundi now owns 2,229,326 shares of the company's stock worth $630,855,000 after purchasing an additional 676,066 shares in the last quarter. Carmignac Gestion boosted its position in Cencora by 58.7% during the second quarter. Carmignac Gestion now owns 1,747,363 shares of the company's stock worth $494,463,000 after purchasing an additional 646,112 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Cencora in the second quarter valued at $483,772,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Transactions at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the business's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.38% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on COR shares. Leerink Partners lifted their target price on shares of Cencora from $380.00 to $388.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 7th. Wells Fargo & Company increased their price target on shares of Cencora from $331.00 to $395.00 and gave the company an "overweight" rating in a research report on Tuesday, August 11th. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $330.00 price target on shares of Cencora in a research report on Tuesday, September 8th. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $382.00 to $390.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Finally, Robert W. Baird lifted their price objective on Cencora from $373.00 to $375.00 and gave the stock an "outperform" rating in a research report on Thursday. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Cencora presently has an average rating of "Moderate Buy" and an average target price of $366.44.

Read Our Latest Stock Report on COR

Cencora Stock Down 2.3%

Shares of NYSE:COR opened at $330.77 on Friday. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market capitalization of $63.12 billion, a P/E ratio of 24.57, a PEG ratio of 1.70 and a beta of 0.58. The stock has a 50-day simple moving average of $322.35 and a 200-day simple moving average of $304.06.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.35 by $0.13. The firm had revenue of $84.75 billion during the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The firm's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.00 EPS. Equities analysts forecast that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Friday, August 14th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 14th. Cencora's payout ratio is currently 17.83%.

Cencora Company Profile

(Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.

Read More

Institutional Ownership by Quarter for Cencora (NYSE:COR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cencora Right Now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines